Cargando…
Nanoparticles for transcutaneous vaccination
The living epidermis and dermis are rich in antigen presenting cells (APCs). Their activation can elicit a strong humoral and cellular immune response as well as mucosal immunity. Therefore, the skin is a very attractive site for vaccination, and an intradermal application of antigen may be much mor...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3815776/ https://www.ncbi.nlm.nih.gov/pubmed/21854553 http://dx.doi.org/10.1111/j.1751-7915.2011.00284.x |
_version_ | 1782289439171543040 |
---|---|
author | Hansen, Steffi Lehr, Claus‐Michael |
author_facet | Hansen, Steffi Lehr, Claus‐Michael |
author_sort | Hansen, Steffi |
collection | PubMed |
description | The living epidermis and dermis are rich in antigen presenting cells (APCs). Their activation can elicit a strong humoral and cellular immune response as well as mucosal immunity. Therefore, the skin is a very attractive site for vaccination, and an intradermal application of antigen may be much more effective than a subcutaneous or intramuscular injection. However, the stratum corneum (SC) is a most effective barrier against the invasion of topically applied vaccines. Products which have reached the stage of clinical testing, avoid this problem by injecting the nano‐vaccine intradermally or by employing a barrier disrupting method and applying the vaccine to a relatively large skin area. Needle‐free vaccination is desirable from a number of aspects: ease of application, improved patient acceptance and less risk of infection among them. Nanocarriers can be designed in a way that they can overcome the SC. Also incorporation into nanocarriers protects instable antigen from degradation, improves uptake and processing by APCs, and facilitates endosomal escape and nuclear delivery of DNA vaccines. In addition, sustained release systems may build a depot in the tissue gradually releasing antigen which may avoid booster doses. Therefore, nanoformulations of vaccines for transcutaneous immunization are currently a very dynamic field of research. Among the huge variety of nanocarrier systems that are investigated hopes lie on ultra‐flexible liposomes, superfine rigid nanoparticles and nanocarriers, which are taken up by hair follicles. The potential and pitfalls associated with these three classes of carriers will be discussed. |
format | Online Article Text |
id | pubmed-3815776 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Blackwell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-38157762014-02-12 Nanoparticles for transcutaneous vaccination Hansen, Steffi Lehr, Claus‐Michael Microb Biotechnol Minireviews The living epidermis and dermis are rich in antigen presenting cells (APCs). Their activation can elicit a strong humoral and cellular immune response as well as mucosal immunity. Therefore, the skin is a very attractive site for vaccination, and an intradermal application of antigen may be much more effective than a subcutaneous or intramuscular injection. However, the stratum corneum (SC) is a most effective barrier against the invasion of topically applied vaccines. Products which have reached the stage of clinical testing, avoid this problem by injecting the nano‐vaccine intradermally or by employing a barrier disrupting method and applying the vaccine to a relatively large skin area. Needle‐free vaccination is desirable from a number of aspects: ease of application, improved patient acceptance and less risk of infection among them. Nanocarriers can be designed in a way that they can overcome the SC. Also incorporation into nanocarriers protects instable antigen from degradation, improves uptake and processing by APCs, and facilitates endosomal escape and nuclear delivery of DNA vaccines. In addition, sustained release systems may build a depot in the tissue gradually releasing antigen which may avoid booster doses. Therefore, nanoformulations of vaccines for transcutaneous immunization are currently a very dynamic field of research. Among the huge variety of nanocarrier systems that are investigated hopes lie on ultra‐flexible liposomes, superfine rigid nanoparticles and nanocarriers, which are taken up by hair follicles. The potential and pitfalls associated with these three classes of carriers will be discussed. Blackwell Publishing Ltd 2012-03 2012-02-20 /pmc/articles/PMC3815776/ /pubmed/21854553 http://dx.doi.org/10.1111/j.1751-7915.2011.00284.x Text en Copyright © 2011 The Authors. Microbial Biotechnology © 2011 Society for Applied Microbiology and Blackwell Publishing Ltd |
spellingShingle | Minireviews Hansen, Steffi Lehr, Claus‐Michael Nanoparticles for transcutaneous vaccination |
title | Nanoparticles for transcutaneous vaccination |
title_full | Nanoparticles for transcutaneous vaccination |
title_fullStr | Nanoparticles for transcutaneous vaccination |
title_full_unstemmed | Nanoparticles for transcutaneous vaccination |
title_short | Nanoparticles for transcutaneous vaccination |
title_sort | nanoparticles for transcutaneous vaccination |
topic | Minireviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3815776/ https://www.ncbi.nlm.nih.gov/pubmed/21854553 http://dx.doi.org/10.1111/j.1751-7915.2011.00284.x |
work_keys_str_mv | AT hansensteffi nanoparticlesfortranscutaneousvaccination AT lehrclausmichael nanoparticlesfortranscutaneousvaccination |